SCHEMBL2301920

SCHEMBL2301920

CCOCC1=Cc2ccccc2[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5602389 0.83 TP53 (0.32)
SCHEMBL5604157 0.76 KDM4E (0.33)
SCHEMBL5602057 0.71 KCNH2 (0.39)
SCHEMBL5602316 0.70 KCNH2 (0.42)
SCHEMBL5601321 0.70 KCNH2 (0.42)
SCHEMBL5602455 0.68 CALM1 (0.42)
SCHEMBL5602978 0.67 TAAR1 (0.36)
SCHEMBL66594 0.63 TSHR (0.35)
Ether SCHEMBL9798107 0.62 MAPT (0.36)
SCHEMBL648250 0.62 IDO1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4759762-B2 2011-08-31 JP claimed
EP-0891331-B1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMA (US) 2003-10-01 EP claimed
EP-0891331-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY Vertex Pharmaceuticals Incorporated (US) 1999-01-20 EP claimed
US-5717092-A Compounds with improved multi-drug resistance activity VERTEX PHARMACEUTICALS INC. (US) 1998-02-10 US claimed
WO-1997036869-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-10-09 WO claimed
US-20240044876-A1 IDENTIFYING NEW THERAPEUTIC AGENTS WARP DRIVE BIO, INC. 2024-02-08 US disclosed
US-11644460-B2 Identifying new therapeutic agents Revolution Medicines, Inc. (US) 2023-05-09 US disclosed
US-10989710-B2 Identifying new therapeutic agents Revolution Medicines, Inc. (US) 2021-04-27 US disclosed
US-20190271691-A1 IDENTIFYING NEW THERAPEUTIC AGENTS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2019-09-05 US disclosed
US-10203323-B2 Identifying new therapeutic agents WARP DRIVE BIO, INC. (US) 2019-02-12 US disclosed
US-20160341719-A1 IDENTIFYING NEW THERAPEUTIC AGENTS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2016-11-24 US disclosed
US-9428845-B1 Identifying new therapeutic agents WARP DRIVE BIO, INC. (US) 2016-08-30 US disclosed
EP-0891331-B1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMA (US) 2003-10-01 EP disclosed
US-5935954-A TREATING THE PATIENT SUFFERING FROM PARKINSON'S DISEASE, ALZHIMER'S DISEASE, STROKE AND ISCHEMIA ASSOCIATED WITH STROKE, NEURAL PAROPATHY, SCIATIC CRUSH, SPINAL CORD INJURY OR FACIAL NERVE CRASH VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-08-10 US disclosed
EP-0891331-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY Vertex Pharmaceuticals Incorporated (US) 1999-01-20 EP disclosed
US-5717092-A Compounds with improved multi-drug resistance activity VERTEX PHARMACEUTICALS INC. (US) 1998-02-10 US disclosed
WO-1997036869-A1 N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-10-09 WO disclosed